A Phase IB Trial of Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 31 Aug 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary) ; Vorolanib (Primary)
- Indications Gastric cancer; Liver cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions
- 19 Jan 2019 Trial design presented at the 2019 Gastrointestinal Cancers Symposium
- 18 Sep 2018 Planned End Date changed from 28 Feb 2022 to 31 Mar 2022.
- 18 Sep 2018 Planned primary completion date changed from 30 Sep 2019 to 31 Oct 2019.